Evaluation of co-morbid conditions among refractory or unexplained chronic cough patients in two phase 2 randomized controlled trials

We assessed a population of refractory or unexplained chronic cough (R/UCC) patients participating in randomized controlled trials of gefapixant, a P2X3 receptor antagonist, to evaluate co-morbid conditions and secondary diagnoses associated with cough. Medical history was examined for patients (cough duration >8 weeks; Cough Severity VAS ≥ 40 mm) participating in two Phase 2 trials of gefapixant: (Study 1) a 2-cohort randomized, controlled,...